Genmab — Marts 2019

[Bella1]

Lidt tilsætning af Sildenafil til Dara kunne nok få den op

[bibob]

Godt klaret med en omsætning på 200 mil og lande et minus på 0,50 øre.

[Bulder]

Under-the-skin https://myelomaresearchnews.com/2019/03/11/under-the-skin-form-as-effective-as-intravenous-darzalex-myeloma/?utm_source=Myeloma+List&utm_campaign=363be747ae-RSS_WEEKLY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_14fcd0022a-363be747ae-72491777

[Bulder]

Selinexor https://myelomaresearchnews.com/2019/03/08/fda-raises-concerns-safety-selinexor-myeloma/?utm_source=Myeloma+List&utm_campaign=363be747ae-RSS_WEEKLY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_14fcd0022a-363be747ae-72491777

[E_L]

Creating Lasting Benefit With CAR T-Cell Therapy in Myeloma
https://www.onclive.com/web-exclusives/creating-lasting-benefit-with-car-tcell-therapy-in-myeloma?p=1

[Helge_LarsenPI-redaktør]

God morgen.

[polle1]

God morgen og god dag

[transalp]

Go morgen derude..

[Helge_LarsenPI-redaktør]

https://play.borsen.dk/social/5c8643b3595ab4f00a32ff35

[E_L]

JNJ has announced that (NICE) has recommended Darzalex (daratumumab) plus Velcade (bortezomib) and dexamethasone (DVd) for use within the Cancer Drugs Fund (CDF), as an option for treating relapsed multiple myeloma in people who have had one previous treatment. https://pharmafield.co.uk/pharma_news/nice-nod-for-game-changing-treatment-via-cdf-for-uk-myeloma-patients/

[E_L]

on NICE https://www.nice.org.uk/guidance/indevelopment/gid-ta10174/documents

[E_L]

Cancer Research UK : ‘Game-changing’ myeloma drug combo approved for NHS use in England ‘Game-changing’ myeloma drug combo approved for NHS use in England

[E_L]

https://www.cancerresearchuk.org/about-us/cancer-news/news-report/2019-03-12-game-changing-myeloma-drug-combo-approved-for-nhs-use-in-england

[Tandfeen-2]

Endelig med nice

[peter12]

I 4. linie regnede de med ca 700 pts https://pharmaphorum.com/news/nice-backs-interim-funding-janssen-cancer-drug/

[E_L]

we are not there yet @Tandfeen-2 , still not 1st line and still via CDF, so far from ideal. But it is another step that will increase sales.

[E_L]

"NICE however said that the overall-survival data was ‘immature’ because more than half of the patients treated with the daratumumab combination were alive after nearly four years of follow up." this sounds like, if patients would have died quicker, it would have been easier to approve… crazy...

[peter12]

Interesting discussion between Janssen and Nice last year
. Dara could reset MM treatment https://www.nice.org.uk/guidance/ta510/documents/committee-papers-2

[Sukkeralf]

E L I guess that comment is because NICE mainly base their reimbursement on OS data

[E_L]

yes, i guess you are correct, that is what they base their cost effectiveness study on, but it feels weird to say that it is difficult to measure because they live too long... Anyway, another small step..
.